サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467660

止血・組織封鎖剤の市場レポート：製品タイプ、材料タイプ、用途、エンドユーザー、地域別、2024～2032年

Hemostasis and Tissue Sealing Agents Market Report by Product Type, Material Type (Collagen-based, Oxidized Regenerated Cellulose based, Gelatin-based, Polysaccharide-based, and Others), Application, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
止血・組織封鎖剤の市場レポート：製品タイプ、材料タイプ、用途、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の止血・組織封鎖剤市場規模は2023年に68億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに119億米ドルに達し、2024～2032年の成長率（CAGR）は6.2％になると予測しています。同市場は、手術件数の増加、製品の有効性、安全性、使いやすさの向上につながる技術の進歩、心血管疾患、がん、糖尿病などの慢性疾患の有病率の増加などを背景に、着実な成長を遂げています。

止血・組織封鎖剤の市場分析：

市場の成長と規模低侵襲（MI）手術への嗜好の高まりと有利な行政施策により、市場は緩やかな成長を示しています。

技術の進歩：高度な生体材料、送達システム、止血特性の向上が市場成長を後押ししています。

産業用途：止血・組織封鎖剤は、心臓血管や整形外科など幅広い外科手術に応用されています。

地域別動向：北米は、高度な医療技術や熟練した医療専門家を利用できる高度に発達した医療インフラがあることから、市場をリードしています。しかし、アジア太平洋は医療インフラの改善により、急成長市場として浮上しています。

競合情勢：主要参入企業は、製品の有効性、安全性、有用性を高めるために、新規の生体材料、製剤、送達システムを探求する研究開発（R&D）活動に投資しています。

課題と機会：同市場は、製品の安全性に関する懸念などの課題に直面する一方で、アンメット・メディカル・ニーズへの対応に注目が高まっていることから、機会にも恵まれています。

将来の展望：高齢者人口の増加に伴い、止血・組織封鎖剤市場の将来は有望です。また、費用対効果や価値別のケアに対するニーズの高まりが市場の成長を後押しすると予想されます。

止血剤と組織封鎖剤の市場動向：

外科手術の増加

世界中の大衆の間で外科手術の件数が増加していることが、止血・組織密封剤市場の成長を支えています。人々は外科的介入を必要とする様々な病気に苦しんでいます。止血・組織封鎖剤は、日常的な処置から複雑な手術に至るまで、様々な外科的介入において出血を制御し、治癒を促進するために不可欠です。さらに、出血性合併症に対処し、患者の転帰を向上させるための効果的な止血・封鎖ソリューションに対するニーズの高まりが、市場の成長を後押ししています。複雑な手術では、組織の剥離や操作が複雑になることが多く、出血性合併症のリスクが高くなります。止血・組織封鎖剤は、こうした課題に対処し、転帰を成功に導く上で重要な役割を果たしています。さらに、腹腔鏡手術やロボット支援手術などのMI手術手技への嗜好の高まりが、市場の成長に寄与しています。MI手術は、外傷の減少や回復時間の短縮といった利点がある一方で、効果的な止血コントロールや組織シーリングが依然として必要であり、これらは特殊な製品によって促進されます。

技術的進歩

止血・組織封鎖剤の技術革新は、製品の有効性、安全性、使いやすさを高めるのに役立っています。これらの進歩には、新規生体材料の開発、高度な送達システムの開発、止血特性の改善などが含まれます。さらに、優れた凝固メカニズムを持つ止血剤や、接着性を強化した組織封鎖剤の導入により、より優れた止血と創傷閉鎖が可能になります。生体適合性材料や生分解性製剤の進歩は、組織適合性や長期安全性に関する懸念に対処するものです。さらに、新しい送達システムにより、止血・組織封鎖剤を手術部位に正確に適用できるようになりました。これらのシステムには、スプレー式アプリケータ、注射製剤、あるいは薬剤の制御された標的送達を可能にする特殊な装置が含まれます。標的送達システムは、手術効率を改善し、無駄を最小限に抑え、止血・組織封鎖剤の効果を高める。このほか、生分解性止血・組織封鎖剤は、時間の経過とともに分解され、体内に吸収されるように設計されているため、その後の除去や介入の必要がないです。

慢性疾患の増加

心血管疾患、がん、糖尿病などの慢性疾患の増加は、止血・組織封鎖剤の需要を刺激しています。慢性疾患は診断、治療、管理のために外科的処置を必要とすることが多いです。ライフスタイルや環境要因、食習慣の変化により、これらの疾病にかかる人が増えています。糖尿病性潰瘍、褥瘡、静脈性潰瘍などの慢性創傷は慢性疾患の一般的な合併症であり、しばしばデブリードマン、創傷閉鎖、管理のための外科的介入を必要とします。このような処置では、止血を促進し、創傷閉鎖を容易にし、治癒を促進するために、止血・組織封鎖剤が使用されます。これとは別に、慢性疾患の患者は、出血や創傷治癒の問題を含む外科的合併症のリスクを増大させる併存疾患や生理学的障害を呈することがあります。止血・組織封鎖剤は、出血を制御し、組織を密封し、最適な創傷治癒を促進することによって、これらのリスクを軽減する上で重要な役割を果たしており、これが市場の成長を支えています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 止血剤・組織密封剤の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • 局所止血材
  • 粘着剤と組織封鎖剤

第7章 市場内訳：材料タイプ別

  • コラーゲン系
  • 酸化再生セルロース（ORC）ベース
  • ゼラチンベース
  • 多糖類ベース
  • その他

第8章 市場内訳：用途別

  • 一般手術
  • 低侵襲手術
  • その他

第9章 市場内訳：エンドユーザー別

  • 病院
  • 外来手術センター
  • 在宅ケア
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Advance Medical Solution Group Plc.
    • Artivion Inc.
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Becton, Dickinson & Company
    • Integra LifeSciences Corporation
    • Johnson & Johnson
    • Medtronic plc
    • Pfizer Inc.
    • Smith & Nephew plc
    • Terumo Corporation
図表

List of Figures

  • Figure 1: Global: Hemostasis and Tissue Sealing Agents Market: Major Drivers and Challenges
  • Figure 2: Global: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Material Type (in %), 2023
  • Figure 6: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Hemostasis and Tissue Sealing Agents Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Hemostasis and Tissue Sealing Agents (Topical Hemostats) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hemostasis and Tissue Sealing Agents (Topical Hemostats) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hemostasis and Tissue Sealing Agents (Adhesive and Tissue Sealant) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hemostasis and Tissue Sealing Agents (Adhesive and Tissue Sealant) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hemostasis and Tissue Sealing Agents (Collagen-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hemostasis and Tissue Sealing Agents (Collagen-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hemostasis and Tissue Sealing Agents (Oxidized Regenerated Cellulose (ORC) based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hemostasis and Tissue Sealing Agents (Oxidized Regenerated Cellulose (ORC) based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hemostasis and Tissue Sealing Agents (Gelatin-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hemostasis and Tissue Sealing Agents (Gelatin-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hemostasis and Tissue Sealing Agents (Polysaccharide-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hemostasis and Tissue Sealing Agents (Polysaccharide-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hemostasis and Tissue Sealing Agents (Other Material Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hemostasis and Tissue Sealing Agents (Other Material Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Hemostasis and Tissue Sealing Agents (General Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Hemostasis and Tissue Sealing Agents (General Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Hemostasis and Tissue Sealing Agents (Minimally Invasive Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Hemostasis and Tissue Sealing Agents (Minimally Invasive Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Hemostasis and Tissue Sealing Agents (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Hemostasis and Tissue Sealing Agents (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Hemostasis and Tissue Sealing Agents (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Hemostasis and Tissue Sealing Agents (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Hemostasis and Tissue Sealing Agents (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Hemostasis and Tissue Sealing Agents (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Hemostasis and Tissue Sealing Agents (Home Care Settings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Hemostasis and Tissue Sealing Agents (Home Care Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Hemostasis and Tissue Sealing Agents (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Hemostasis and Tissue Sealing Agents (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Hemostasis and Tissue Sealing Agents Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Hemostasis and Tissue Sealing Agents Industry: SWOT Analysis
  • Figure 87: Global: Hemostasis and Tissue Sealing Agents Industry: Value Chain Analysis
  • Figure 88: Global: Hemostasis and Tissue Sealing Agents Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemostasis and Tissue Sealing Agents Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Material Type (in Million US$), 2024-2032
  • Table 4: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Hemostasis and Tissue Sealing Agents Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Hemostasis and Tissue Sealing Agents Market: Competitive Structure
  • Table 8: Global: Hemostasis and Tissue Sealing Agents Market: Key Players
目次
Product Code: SR112024A6397

The global hemostasis and tissue sealing agents market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. The market is experiencing steady growth driven by rising number of surgical procedures, technological advancements leading to enhanced product efficacy, safety, and ease of use, and increasing prevalence of chronic diseases, such as cardiovascular ailments, cancer, and diabetes.

Hemostasis and Tissue Sealing Agents Market Analysis:

Market Growth and Size: The market is witnessing moderate growth on account of increasing preferences for minimally invasive (MI) surgeries, along with favorable governing initiatives.

Technological Advancements: Advanced biomaterials, delivery systems, and improved hemostatic properties are propelling the market growth.

Industry Applications: Hemostasis and tissue sealing agents find applications across a wide range of surgical procedures, including cardiovascular and orthopedic.

Geographical Trends: North America leads the market, driven by the presence of highly developed healthcare infrastructure with access to advanced medical technologies and skilled healthcare professionals. However, Asia Pacific is emerging as a fast-growing market due to the improving healthcare infrastructure.

Competitive Landscape: Key players are investing in research and development (R&D) activities to explore novel biomaterials, formulations, and delivery systems for enhancing product efficacy, safety, and usability.

Challenges and Opportunities: While the market faces challenges, such as product safety concerns, it also encounters opportunities on account of the rising focus on addressing unmet medical needs.

Future Outlook: The future of the hemostasis and tissue sealing agents market looks promising with the increasing geriatric population. In addition, the rising need for cost-effectiveness and value-based care is anticipated to bolster the market growth.

Hemostasis and Tissue Sealing Agents Market Trends:

Rising number of surgical procedures

The increasing number of surgical procedures among the masses across the globe is supporting the hemostasis and tissue sealing agents market growth. People are suffering from various diseases that require surgical intervention. Hemostasis and tissue sealing agents are vital for controlling bleeding and promoting healing during various surgical interventions, ranging from routine procedures to complex surgeries. Additionally, the rising need for effective hemostatic and sealing solutions to address bleeding complications and enhance patient outcomes is propelling the market growth. Complex surgeries often involve intricate tissue dissection and manipulation, leading to a higher risk of bleeding complications. Hemostasis and tissue sealing agents play a critical role in addressing these challenges and ensuring successful outcomes. Furthermore, increasing preferences for MI surgical techniques, such as laparoscopic and robotic-assisted procedures, are contributing to the market growth. While MI surgeries offer benefits like reduced trauma and faster recovery times, they still require effective hemostatic control and tissue sealing, which are facilitated by specialized products.

Technological Advancements

Technological innovations in hemostasis and tissue sealing agents assist in enhancing product efficacy, safety, and ease of use. These advancements include the development of novel biomaterials, advanced delivery systems, and improved hemostatic properties. Moreover, the introduction of hemostatic agents with superior clotting mechanisms and tissue sealants with enhanced adhesive properties enable better hemostasis and wound closure. Advancements in biocompatible materials and biodegradable formulations address concerns regarding tissue compatibility and long-term safety. Furthermore, novel delivery systems enable the precise application of hemostasis and tissue sealing agents to the surgical site. These systems include spray applicators, injectable formulations, or specialized devices that allow for controlled and targeted delivery of the agents. Targeted delivery systems improve surgical efficiency, minimize wastage, and enhance the effectiveness of hemostasis and tissue sealing agents. Besides this, biodegradable hemostasis and tissue sealing agents are designed to degrade over time and be absorbed by the body, eliminating the need for subsequent removal or intervention.

Increasing prevalence of chronic diseases

The growing prevalence of chronic diseases, such as cardiovascular ailments, cancer, and diabetes, is catalyzing demand for hemostasis and tissue sealing agents. Chronic conditions often require surgical procedures for diagnosis, treatment, or management. People are increasingly suffering from these diseases due to changing lifestyles, environmental factors, and eating habits. Chronic wounds, such as diabetic ulcers, pressure ulcers, and venous ulcers, are common complications of chronic diseases and often require surgical intervention for debridement, closure, or management. Hemostasis and tissue sealing agents are utilized in these procedures to promote hemostasis, facilitate wound closure, and accelerate healing. Apart from this, patients with chronic diseases may present with comorbidities or physiological impairments that increase the risk of surgical complications, including bleeding and wound healing issues. Hemostasis and tissue sealing agents play a critical role in mitigating these risks by controlling bleeding, sealing tissues, and promoting optimal wound healing, which is supporting the market growth.

Hemostasis and Tissue Sealing Agents Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, material type, application, and end user.

Breakup by Product Type:

Topical Hemostats

Adhesive and Tissue Sealant

Topical hemostats account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes topical hemostats and adhesive and tissue sealant. According to the report, topical hemostats represented the largest segment.

Topical hemostats are agents applied directly to the bleeding site to control bleeding. They are available in various forms, such as powders, gels, sponges, and patches. These hemostats work by promoting coagulation, accelerating clot formation, or enhancing platelet aggregation to achieve hemostasis. They are particularly useful in surgical procedures where direct pressure or conventional methods may not be sufficient to achieve hemostasis.

Adhesive and tissue sealant products are used to seal tissues, close wounds, or bond tissues together. They are available in liquid, gel, or film forms and are applied directly to the tissue surface. These products contain biocompatible materials that adhere to the tissue surface and create a barrier, promoting wound healing and preventing leakage or further bleeding.

Breakup by Material Type:

Collagen-based

Oxidized Regenerated Cellulose (ORC) based

Gelatin-based

Polysaccharide-based

Others

A detailed breakup and analysis of the market based on the material type have also been provided in the report. This includes collagen-based, oxidized regenerated cellulose (ORC) based, gelatin-based, polysaccharide-based, and others.

Collagen-based hemostats utilize collagen, a protein found in connective tissues. Collagen promotes platelet adhesion and activation, initiating the clotting cascade to achieve hemostasis. Collagen-based hemostats are available in various forms, such as sponges, powders, or patches, and are widely used in surgical procedures across different specialties.

Oxidized regenerated cellulose (ORC) based hemostats are derived from cellulose, a polysaccharide found in plants. Through a process of oxidation and regeneration, cellulose is converted into ORC, which possesses hemostatic properties. ORC-based hemostats work by promoting platelet aggregation and accelerating clot formation at the bleeding site. They are available in different forms like gauzes, pads, or powders and are commonly used in surgeries where rapid hemostasis is required.

Gelatin-based hemostats are derived from collagen obtained from animal sources, usually bovine or porcine. Gelatin possesses hemostatic properties and is often combined with thrombin or other clotting factors to enhance its efficacy. These hemostats come in various forms, such as sponges, powders, or sheets, and are used in surgical procedures to control bleeding and promote wound healing.

Polysaccharide-based hemostats utilize polysaccharides, complex carbohydrates found in plants or animals. These hemostats work by promoting platelet activation and aggregation, facilitating clot formation. Polysaccharide-based hemostats include products derived from substances like chitosan, alginate, or starch. They are available in different forms like powders, gels, or films and are utilized in surgical procedures to achieve hemostasis and promote tissue sealing.

Breakup by Application:

General Surgery

Minimally Invasive Surgery

Others

General surgery represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes general surgery, minimally invasive surgery, and others. According to the report, general surgery represented the largest segment.

General surgery encompasses a wide range of surgical procedures involving various organs and tissues within the body. These surgeries can include procedures, such as appendectomies, hernia repairs, gallbladder removals, and bowel surgeries. Hemostasis and tissue sealing agents play a crucial role in general surgery by controlling bleeding, sealing tissues, and promoting wound healing. These agents are used to manage bleeding from incisions, dissected tissues, and damaged vessels, ensuring optimal surgical outcomes and patient recovery.

Minimally invasive surgery (MIS), also known as laparoscopic or keyhole surgery, involves performing surgical procedures through small incisions using specialized instruments and a camera for visualization. MIS offers several advantages as compared to traditional open surgery, such as reduced post-operative pain, shorter hospital stays, and quicker recovery times. In minimally invasive (MI) procedures, hemostasis and tissue sealing agents are essential for controlling bleeding and sealing tissues through small incisions. These agents are applied directly to the surgical site to achieve hemostasis and ensure optimal tissue closure.

Breakup by End User:

Hospitals

Ambulatory Surgical Centers

Home Care Settings

Others

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory surgical centers, home care settings, and others.

Hospitals serve as primary settings for a wide range of medical interventions, including surgical procedures requiring hemostasis and tissue sealing agents. These facilities encompass various departments, such as operating rooms, emergency departments, and specialty units, where surgeries are performed. Hospitals have comprehensive resources, including specialized equipment, trained personnel, and integrated healthcare services, making them key users of hemostasis and tissue sealing agents. These agents are used across different surgical specialties within hospital settings to control bleeding, seal tissues, and promote wound healing.

Ambulatory surgical centers (ACSs), also known as outpatient surgery centers or day surgery centers, provide surgical services on an outpatient basis, allowing patients to undergo procedures without overnight hospitalization. ASCs offer a convenient and cost-effective alternative to traditional hospital-based surgeries, particularly for minor or elective procedures. In ASCs, hemostasis and tissue sealing agents are utilized to control bleeding and promote wound closure during various surgical interventions. These centers often specialize in specific surgical specialties, such as ophthalmology, orthopedics, or gastroenterology, where hemostasis and tissue sealing agents are routinely used to ensure safe and efficient surgical outcomes.

Home care settings involve the provision of medical care, including post-operative care, within the home of patients. Hemostasis and tissue sealing agents are used to address wound complications, promote healing, and prevent infections, ensuring continuity of care and facilitating the recovery process of patients within the comfort of their homes.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest hemostasis and tissue sealing agents market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share due to the presence of highly developed healthcare infrastructure, with access to advanced medical technologies and skilled healthcare professionals. Additionally, the rising number of surgical procedures among individuals is bolstering the market growth.

Asia Pacific stands as another key region in the market, driven by the increasing adoption of MI surgeries among the masses. In addition, improving healthcare infrastructure is contributing to the growth of the market.

Europe maintains a strong presence in the market, with the rising prevalence of chronic diseases among individuals. Besides this, stringent standards for the approval and marketing of medical devices, including hemostasis and tissue sealing agents, are impelling the market growth.

Latin America exhibits the growing potential in the market on account of the increasing need for hemostasis and tissue sealing agents during surgical interventions. Furthermore, the rising awareness among healthcare professionals and patients about the benefits of advanced surgical techniques and medical products is bolstering the market growth.

The Middle East and Africa region is primarily driven by improving healthcare infrastructure. Moreover, thriving medical tourism in the region is propelling the market growth.

Leading Key Players in the Hemostasis and Tissue Sealing Agents Industry:

Key players are investing in R&D activities to explore novel biomaterials, formulations, and delivery systems to enhance product efficacy, safety, and usability. They are continuously innovating their product offerings to meet the diverse needs of healthcare providers and patients by developing advanced hemostatic agents and tissue sealants with enhanced hemostatic properties, faster sealing times, and improved biocompatibility. In addition, companies are expanding the indications for their hemostasis and tissue sealing agents, making them applicable to a wider range of surgical procedures. This involves obtaining regulatory approvals for new indications and conducting clinical trials to demonstrate product efficacy and safety in different surgical specialties. Furthermore, companies are expanding their market reach by entering new geographical regions.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Advance Medical Solution Group Plc.

Artivion Inc.

B. Braun Melsungen AG

Baxter International Inc.

Becton, Dickinson & Company

Integra LifeSciences Corporation

Johnson & Johnson

Medtronic plc

Pfizer Inc.

Smith & Nephew plc

Terumo Corporation

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

July 29, 2021: Baxter International Inc completed the acquisition of certain assets related to PerClot polysaccharide hemostatic system from CryoLife, Inc. PerClot further enhances the ability of the company to optimize patient care by addressing a broad range of intraoperative bleeding with both active and passive hemostatic solutions.

November 15, 2023: Johnson & Johnson MedTech company 'Ethicon' announced the approval of ETHIZIATM, an adjunctive hemostat solution, which is clinically proven to achieve sustained hemostasis in difficult to control bleeding situations.

February 26, 2020: Terumo Corporation launched AQUABRID(R) a new surgical sealant especially developed for aortic procedures. It reacts with blood and forms an elastic layer that adheres tightly to the tissue. It is safe and effective in achieving hemostasis, even when blood coagulation is inhibited during cardiac surgery.

Key Questions Answered in This Report

  • 1. What was the size of the global hemostasis and tissue sealing agents market in 2023?
  • 2. What is the expected growth rate of the global hemostasis and tissue sealing agents market during 2024-2032?
  • 3. What are the key factors driving the global hemostasis and tissue sealing agents market?
  • 4. What has been the impact of COVID-19 on the global hemostasis and tissue sealing agents market?
  • 5. What is the breakup of the global hemostasis and tissue sealing agents market based on the product type?
  • 6. What is the breakup of the global hemostasis and tissue sealing agents market based on the application?
  • 7. What are the key regions in the global hemostasis and tissue sealing agents market?
  • 8. Who are the key players/companies in the global hemostasis and tissue sealing agents market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemostasis and Tissue Sealing Agents Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Topical Hemostats
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Adhesive and Tissue Sealant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Material Type

  • 7.1 Collagen-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxidized Regenerated Cellulose (ORC) based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Gelatin-based
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Polysaccharide-based
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Application

  • 8.1 General Surgery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Minimally Invasive Surgery
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Home Care Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Advance Medical Solution Group Plc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Artivion Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 B. Braun Melsungen AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Baxter International Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Becton, Dickinson & Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Integra LifeSciences Corporation
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Johnson & Johnson
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Medtronic plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Smith & Nephew plc
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Terumo Corporation
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis